Zobrazeno 1 - 10
of 345
pro vyhledávání: '"Robert W Wilkinson"'
Autor:
Suzanne I. Sitnikova, Jennifer A. Walker, Laura B. Prickett, Michelle Morrow, Viia E. Valge-Archer, Matthew J. Robinson, Robert W. Wilkinson, Simon J. Dovedi
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionImmuno-oncology (IO) research relies heavily on murine syngeneic tumor models. However, whilst the average age for a cancer diagnosis is 60 years or older, for practical purposes the majority of preclinical studies are conducted in young
Externí odkaz:
https://doaj.org/article/1b4f24a133924f28b0538a31b1ac7be8
Publikováno v:
SLAS Discovery, Vol 27, Iss 2, Pp 95-106 (2022)
The field of Immuno-Oncology (IO) is evolving to utilise novel antibody backbones that can co-target multiple cell-surface stimulatory and inhibitory co-receptors (SICR). This approach necessitates a better understanding of SICR co-expression at the
Externí odkaz:
https://doaj.org/article/9087a34ea27f4b3ea19c5bd2348d173a
Autor:
Marta Lopez-Pelaez, Lucy Young, Mercedes Vazquez-Chantada, Nadine Nelson, Steve Durant, Robert W. Wilkinson, Edmund Poon, Miguel Gaspar, Viia Valge-Archer, Paul Smith, Simon J. Dovedi
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
The concept of exploiting tumor intrinsic deficiencies in DNA damage repair mechanisms by inhibiting compensatory DNA repair pathways is well established. For example, ATM-deficient cells show increased sensitivity to the ATR inhibitor ceralasertib.
Externí odkaz:
https://doaj.org/article/9d2d450388024f9abe63eda60fc9f35d
Autor:
Robert W Wilkinson, Hormas Ghadially, Stacy Kentner, Suzanne Isabelle Sitnikova, Sophie Munnings-Tomes, Elena Galvani, Kathy Mulgrew, Chris Rands, Judit España Agustí, Tianhui Zhang, Kristina M Ilieva, Guglielmo Rosignoli, Matthew J Robinson, Tim Slidel, Simon J Dovedi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 6 (2021)
Background Immuno-oncology therapies are now part of the standard of care for cancer in many indications. However, durable objective responses remain limited to a subset of patients. As such, there is a critical need to identify biomarkers that can p
Externí odkaz:
https://doaj.org/article/0daba65ab2174eb2906d5b3b2486abf0
Autor:
Stefanie R. Mullins, John P. Vasilakos, Katharina Deschler, Iwen Grigsby, Pete Gillis, Julius John, Matthew J. Elder, John Swales, Elina Timosenko, Zachary Cooper, Simon J. Dovedi, Andrew J. Leishman, Nadia Luheshi, James Elvecrog, Ashenafi Tilahun, Richard Goodwin, Ronald Herbst, Mark A. Tomai, Robert W. Wilkinson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-18 (2019)
Abstract Background Immune checkpoint blockade (ICB) promotes adaptive immunity and tumor regression in some cancer patients. However, in patients with immunologically “cold” tumors, tumor-resident innate immune cell activation may be required to
Externí odkaz:
https://doaj.org/article/664a845e229648008b22d687ebf6b261
Autor:
Nadine Nelson, Marta Lopez-Pelaez, Asis Palazon, Edmund Poon, Maike De La Roche, Simon Barry, Viia Valge-Archer, Robert W. Wilkinson, Simon J. Dovedi, Paul D. Smith
Publikováno v:
OncoImmunology, Vol 8, Iss 8, Pp 1-10 (2019)
In vitro assays that evaluate CD8+ T cell-mediated cytotoxicity are important to aid in the development of novel therapeutic approaches to enhance anti-tumor immune responses. Here, we describe a novel cytotoxicity co-culture assay that circumvents t
Externí odkaz:
https://doaj.org/article/bef43dac3ea74350878e6dc63b21d270
Autor:
Darren J. Schofield, Jennifer Percival-Alwyn, Mateusz Rytelewski, John Hood, Raymond Rothstein, Leslie Wetzel, Kelly McGlinchey, Grace Adjei, Amanda Watkins, LeeAnn Machiesky, Weimin Chen, John Andrews, Maria Groves, Michelle Morrow, Ross A. Stewart, Andrew Leinster, Robert W. Wilkinson, Scott A. Hammond, Nadia Luheshi, Claire Dobson, Michael Oberst
Publikováno v:
mAbs, Vol 13, Iss 1 (2021)
Preclinical studies of PD-L1 and CTLA-4 blockade have relied heavily on mouse syngeneic tumor models with intact immune systems, which facilitate dissection of immunosuppressive mechanisms in the tumor microenvironment. Commercially developed monoclo
Externí odkaz:
https://doaj.org/article/5b7084f79f5a4c06ad3eff39bdaa115c
Autor:
Mark Austin, Daniel Burschowsky, Denice T.Y. Chan, Lesley Jenkinson, Stuart Haynes, Agata Diamandakis, Chitra Seewooruthun, Alexandra Addyman, Sebastian Fiedler, Stephanie Ryman, Jessica Whitehouse, Louise H. Slater, Andreas V. Hadjinicolaou, Uzi Gileadi, Ellen Gowans, Yoko Shibata, Michelle Barnard, Teresa Kaserer, Pooja Sharma, Nadia M. Luheshi, Robert W. Wilkinson, Tristan J. Vaughan, Sarah V. Holt, Vincenzo Cerundolo, Mark D. Carr, Maria A. T. Groves
Publikováno v:
mAbs, Vol 12, Iss 1 (2020)
Arginase 2 (ARG2) is a binuclear manganese metalloenzyme that catalyzes the hydrolysis of L-arginine. The dysregulated expression of ARG2 within specific tumor microenvironments generates an immunosuppressive niche that effectively renders the tumor
Externí odkaz:
https://doaj.org/article/e9b2ccb330b0476b8cb004d93c4045cc
Autor:
Damien J Zanker, Alex J Spurling, Natasha K Brockwell, Katie L Owen, Jasmine M Zakhour, Tina Robinson, Hendrika M Duivenvoorden, Paul J Hertzog, Stefanie R Mullins, Robert W Wilkinson, Belinda S Parker
Publikováno v:
Clinical & Translational Immunology, Vol 9, Iss 9, Pp n/a-n/a (2020)
Abstract Objectives Loss of tumor‐inherent type I interferon (IFN) signalling has been closely linked to accelerated metastatic progression via decreased immunogenicity and antitumor immunity. Previous studies in murine models of triple‐negative
Externí odkaz:
https://doaj.org/article/61578605bee846698ae1d74398aee779
Autor:
Juliana B. Candido, Jennifer P. Morton, Peter Bailey, Andrew D. Campbell, Saadia A. Karim, Thomas Jamieson, Laura Lapienyte, Aarthi Gopinathan, William Clark, Ewan J. McGhee, Jun Wang, Monica Escorcio-Correia, Raphael Zollinger, Rozita Roshani, Lisa Drew, Loveena Rishi, Rebecca Arkell, T.R. Jeffry Evans, Colin Nixon, Duncan I. Jodrell, Robert W. Wilkinson, Andrew V. Biankin, Simon T. Barry, Frances R. Balkwill, Owen J. Sansom
Publikováno v:
Cell Reports, Vol 23, Iss 5, Pp 1448-1460 (2018)
Summary: Pancreatic ductal adenocarcinoma (PDAC) is resistant to most therapies including single-agent immunotherapy and has a dense desmoplastic stroma, and most patients present with advanced metastatic disease. We reveal that macrophages are the d
Externí odkaz:
https://doaj.org/article/45c8c19d20b94803a6045e1c8286f6ed